Wikisage, the free encyclopedia of the second generation, is digital heritage

Difference between revisions of "Belzutifan"

From Wikisage
Jump to navigation Jump to search
(External links)
Line 1: Line 1:
Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease.
+
Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von [[Hippel-Lindau disease]].
  
 
Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).
 
Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).

Revision as of 23:54, 13 August 2021

Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease.

Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).

Belzutifan is the first drug to be awarded an "innovation passport" by the UK Medicines and Healthcare products Regulatory Agency (MHRA)[1]

ATC

none

Belzutifan.png
belzutifan

Buecher Regal 636.jpg Retinal angioma associated with cerebellar angioma and sometimes angioma in other organs[2]

VHL protein

External links

Ben-Skowronek I, Kozaczuk S 2015: Von Hippel-Lindau Syndrome. Horm Res Paediatr 84:145-152. doi: 10.1159/000431323

Q27456641 op Wikidata  Interwiki via Wikidata


References

References: